Concepedia

Author

Christoph Koenen

Novo Nordisk (Denmark)

Also Known As

C Koenen, C. Koenen, Christoph Koenen

15

Publications

990

Citations

8

H-Index

13

Concepts

All Affiliations

Novo Nordisk (Denmark)University of MiamiDiabetes Care CenterDiabetes Research CenterNovo Nordisk (United States)
CK

About

Christoph Koenen is an author at Novo Nordisk (Denmark) specializing in diabetes, medicine, and diabetes complications.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

244

2

Diabetes

3

3

244

3

Public Health

2

2

151

4

Biostatistics

2

2

151

5

Health Policy

2

2

151

Christoph Koenen

×

8

Publications

973

Citations

8

H-Index

YearCitations

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

Julio Rosenstock, Melanie J. Davies, Philip Home,

Diabetologia

2008

446

The usage of a simplified self‐titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study

Luigi Meneghini, Christoph Koenen, Wayne Weng,

Diabetes Obesity and Metabolism

2007

126

Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study*

L. F. Meneghini, Kirsten Rosenberg, Christoph Koenen,

Diabetes Obesity and Metabolism

2006

100

Comparison of insulin detemir and insulin glargine in a basal—bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: A 52-week, multinational, randomized, open-label, parallel-group, Treat-to-Target noninferiority trial

Simon Heller, Christoph Koenen, Bruce W. Bode

Clinical Therapeutics

2009

93

Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVETM European cohort

Anne Dornhorst, H-J Lüddeke, Séamus Sreenan,

International Journal of Clinical Practice

2007

83

Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal‐only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14‐week follow‐up data from PREDICTIVE™

Anne Dornhorst, H.‐J. Lüddeke, Christoph Koenen,

Diabetes Obesity and Metabolism

2007

56

Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study

Jean-Louis Selam, Christoph Koenen, Wayne Weng,

Current Medical Research and Opinion

2008

44

Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study

Jean-Louis Sélam, Christoph Koenen, Wayne Weng,

Current Medical Research and Opinion

2008

25

Page 1